Protean PTEN: Form and function

被引:342
作者
Waite, KA
Eng, C
机构
[1] Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Clin Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA
关键词
D O I
10.1086/340026
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations distributed across the PTEN tumor-suppressor gene have been found to result in a wide spectrum of phenotypic features. Originally shown to be a major susceptibility gene for both Cowden syndrome (CS), which is characterized by multiple hamartomas and an increased risk of breast, thyroid, and endometrial cancers, and Bannayan-Riley-Ruvalcaba syndrome, which is characterized by lipomatosis, macrocephaly, and speckled penis, the PTEN hamartoma tumor syndrome spectrum has broadened to include Proteus syndrome and Proteus-like syndromes. Exon 5, which encodes the core motif, is a hotspot for mutations likely due to the biology of the protein. PTEN is a major lipid 3-phosphatase, which signals down the PI3 kinase/AKT proapoptotic pathway. Furthermore, PTEN is a protein phosphatase, with the ability to dephosphorylate both serine and threonine residues. The protein-phosphatase activity has also been shown to regulate various cell-survival pathways, such as the mitogen-activated kinase (MAPK) pathway. Although it is well established that PTEN's lipid-phosphatase activity, via the PI3K/AKT pathway, mediates growth suppression, there is accumulating evidence that the protein-phosphatase/MAPK pathway is equally important in the mediation of growth arrest and other crucial cellular functions.
引用
收藏
页码:829 / 844
页数:16
相关论文
共 122 条
  • [1] Balanced translocation of 10q and 13q, including the PTEN gene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-Riley-Ruvalcaba syndrome
    Ahmed, SF
    Marsh, DJ
    Weremowicz, S
    Morton, CC
    Williams, DM
    Eng, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12) : 4665 - 4670
  • [2] Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.3.CO
  • [3] 2-I
  • [4] PTEN mutations are uncommon in Proteus syndrome
    Barker, K
    Martinez, A
    Wang, R
    Bevan, S
    Murday, V
    Shipley, J
    Houlston, R
    Harper, J
    [J]. JOURNAL OF MEDICAL GENETICS, 2001, 38 (07) : 480 - 481
  • [5] Biesecker LG, 1999, AM J MED GENET, V84, P389, DOI 10.1002/(SICI)1096-8628(19990611)84:5<389::AID-AJMG1>3.0.CO
  • [6] 2-O
  • [7] Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO
  • [8] 2-0
  • [9] PTEN expression is reduced in a subset of sporadic thyroid carcinomas:: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1
    Bruni, P
    Boccia, A
    Baldassarre, G
    Trapasso, F
    Santoro, M
    Chiappetta, G
    Fusco, A
    Viglietto, G
    [J]. ONCOGENE, 2000, 19 (28) : 3146 - 3155
  • [10] Carethers JM, 1998, CANCER RES, V58, P2724